Search Results

March 2022 Confo Therapeutics Doses First Subjects In Phase 1 Clinical Trial Of CFTX-1554 For The Treatment discovery of medicines targeting G-protein coupled receptors (GPCRs), today announced that the first subjects The Phase 1 study will assess the safety, tolerability and pharmacokinetics of CFTX-1554 in healthy subjects

February 2022 Trevena Announces Submission of New Drug Application in China for OLINVYK® by its Partner Jiangsu Nhwa Pharmaceutical "Submission supported by data from a Phase 3 bridging study of oliceridine injection compared to IV morphine, conducted in China by Nhwa Trevena is eligible to receive future success disorders, today announced that China’s National Medical Products Administration (NMPA) has accepted submission The NDA was submitted by Trevena’s partner, Jiangsu Nhwa Pharmaceutical, and follows completion by Nhwa

October 2022 "Lysosomes coordinate cellular metabolism and growth upon sensing of essential nutrients, including cholesterol. Through bioinformatic analysis of lysosomal proteomes, we identified lysosomal cholesterol signaling (LYCHOS, previously annotated as G protein-coupled receptor 155), a multidomain transmembrane protein that enables cholesterol-dependent activation of the master growth regulator, the protein kinase mechanistic target of rapamycin complex 1 (mTORC1). Cholesterol bound to the amino-terminal permease-like region of LYCHOS, and mutating this site impaired mTORC1 activation. At high cholesterol concentrations, LYCHOS bound to the GATOR1 complex, a guanosine triphosphatase (GTPase)-activating protein for the Rag GTPases, through a conserved cytoplasm-facing loop. By sequestering GATOR1, LYCHOS promotes cholesterol- and Rag-dependent recruitment of mTORC1 to lysosomes. Thus, LYCHOS functions in a lysosomal pathway for cholesterol sensing and couples cholesterol concentrations to mTORC1-dependent anabolic signaling." Read more at the source #DrGPCR #GPCR #IndustryNews

At CA1-subicular presynaptic terminals 5-HT1B and GABAB receptors colocalize.

Subsequent experiments using primary astrocyte cultures revealed that Gi -DREADD stimulation significantly of the astrocytic Gi pathway attenuated intracellular calcium transients triggered by LPS treatment, suggesting

Crystal structures suggest ligand access to the orthosteric binding site of MT1 and MT2 receptors through The side-chain flexibility of Tyr5.38 was significantly different in the two receptor subtypes, as assessed Our simulations also suggest that the open state of Tyr5.38 generates a small pocket on the surface of

Neuronal Gα subunits required for the control of response to polystyrene nanoparticles in the range of

Many cause receptor misfolding and failure to reach the cell surface. that engage nascent mutant GPCRs in the endoplasmic reticulum, stabilizing folding and "rescuing" cell surface We previously demonstrated rescue of cell surface expression of luteinizing hormone receptor mutants Cell surface expression was severely reduced to ≤18% of wild-type (WT) for 11, modestly reduced to 66% of certain mutant FSHRs with severely reduced cell surface expression.

intracellular context ("in-cell") or those focused on characterizing molecules or events at the cell surface some key NMR techniques applied for on-cell NMR studies through both solution- and solid-state NMR and survey focus on the application of on-cell NMR spectroscopy to characterize ligand interactions with cell surface We also provide a brief survey of the applicability of on-cell NMR approaches to other classes of cell surface molecules.

present study examined the interaction between D2 and GABAB receptors using transient applications of sub-saturating heterologous facilitation was modelled based on the known cooperative interaction between the G protein βγ subunits The results suggest that the cooperative interaction between G βγ subunits and GIRK channels determines

The TAS1R2 and TAS1R3 subunits are members of a small family of class C GPCRs whose members share the TAS1R2 contains the primary binding site for most of the sweet-tasting compounds, including natural sugars ligand affinities of hTAS1R2-VFT were drastically reduced through the introduction of single amino acid substitutions

This review focuses on the role of neuropeptides in maintaining the homeostasis of the ocular surface

August 2022 Addex and Indivior Extend GABAB Positive Allosteric Modulator Research Collaboration for Substance agreement with Indivior PLC (LON: INDV) for discovering and developing novel oral gamma-aminobutyric acid subtype

In the full lecture, you will learn how this approach removes subjectivity from interpretation. It avoids overestimating subtype separation.

They utilize synthetic genes, oligo pools, and NGS target enrichment to enhance lives and promote sustainability Interest in this receptor has surged recently due to its involvement in several inflammatory pathologies A deep understanding of the structure-activity relationship helps identify a suitable location for the The final step involves introducing fluorophores suitable for the desired assays. Using our proprietary technology, several linkers were assembled , combining the suitable functionalized

biotech leadership, ambition opens opportunity, but strategic discipline turns scientific potential into sustainable One validated mechanism suggests multiple indications. With every experiment, the opportunity surface expands . If the science supports it, why not pursue it? concentrating resources, the company increases the probability that future expansion will be funded, supported

Subscribe to stay current as new videos are released: ▶️ https://www.youtube.com/@TerryPharmacologyCorner lectures Monthly live AMAs for real-time scientific discussion A continually expanding on-demand archive Sustained Sustained exposure is where judgment sharpens.

On the surface, this looks like a strength. There is movement across the board. This creates a subtle but powerful shift. From the outside, investors start to ask subtle questions. What is the real bet? The science supports it. The data is promising. The market opportunity is real. If it succeeds, does it materially strengthen your negotiating position?

β-arrestin recruitment, receptor internalization, calcium flux, ligand binding, and integrated discovery support Institutional and team memberships receive discounted rates to support coordinated participation. This is not a content subscription. It is structured access to a field. It supports scientists refining expertise. It strengthens teams executing discovery programs.

DiscoverX , a global leader in GPCR product solutions including cell-based assay product solutions supporting drug discovery, development, and regulatory submission. This partnership is designed to support the GPCR research community by expanding access to validated, Their cell-based assays support a wide range of mechanisms of action, including cAMP accumulation, β-arrestin These assays are widely accepted by industry and regulators and are supported by thousands of peer-reviewed

It is designed as a continuous learning environment — supporting scientific reasoning as programs mature The next live AMA will take place: Thursday, February 26th at 12:00 PM EST You are invited to submit antagonism or obscuring subtle allosteric behavior. Key diagnostic considerations: Curved Schild plots suggest occupancy-limited modulation Linear plots High-expression systems maximize detection sensitivity and can reveal subtle efficacies.

In reality, something more subtle starts to shift. 👉 Decision-making changes. They surface only after commitments have already been made. When building quietly turns into surviving 👉 At a certain point, many biotech founders  believe they are still building the company, while in reality, they have already shifted into survival mode. They mean something more subtle. The company is reacting instead of choosing.

events: 12th Adhesion GPCR Workshop; GPCRnet International Symposium; 5th GPCRs Targeted Drug Discovery Summit This soft launch prioritizes usability and clarity to support stronger GPCR drug discovery decisions Subscribe to the free Kenakin Brief Newsletter to join the AMA . Submit your work today ➤ Why Dr. It supports scientists refining expertise. It strengthens teams executing discovery programs.

. 👉 What actually happens is more subtle. Hiring decisions are pulled forward to support a story. In strong biotech startups, they surface as reasonable adjustments that seem aligned with reality. Roles are added to demonstrate scale, even when the organization is not structurally ready to support Under these conditions, decision making begins to shift subtly.

The Ames test, a foundational bacterial assay, surfaces as an early alert for DNA-modifying liabilities High-Dose Investigations Regulatory guidance requires toxic effects to be observed—if achievable—at sufficiently

🔍 This Week in Dr.GPCR Premium: Sneak Peek Upcoming events:  5th GPCRs Targeted Drug Discovery Summit Here's how: Watch the course trailer ➤ Read the blog post ➤ Subscribe to the Kenakin Brief ➤ Dr. Your membership also supports open educational resources for the global GPCR community, ensuring depth guidance on career paths, choosing research topics, switching fields, and learning from both failures and successes

Sustainable biotech growth depends on leaders reinforcing direction as decisions accumulate, not on perfect Founders who prevent silent failure do not wait for problems to surface. ✅ They continuously reinforce

Investor calls take too long before reaching substance. Clear biotech positioning creates the conditions where scientific depth supports confident decisions The most damaging effect is subtle. ✅ Founders start adapting their message in real time , trying to Improving slides or polishing the pitch may reduce surface-level friction, but the core problem remains Science supports the conversation instead of driving it off course. ✅ The result is not smoother selling

. 👉 It feels logical to evaluate success where it is most visible . quietly shapes everything that follows , not through dramatic moves or bold announcements, but through subtle 👉 Milestones, progress signals, and success criteria are often assumed rather than agreed upon. Before assumptions turn into dogma. ✅ Early strategic decision-making does not guarantee success, but They focus on creating a clear decision environment that supports consistent execution later on.

. ✅ This is where survival is decided. Early-stage biotech hiring is not about perfect resumes. They are never sufficient. that survival traits are not abstract qualities. Survival traits determine whether anything gets done when they are not. How Founders Can Hire for Survival Without Overengineering It 👉 Once founders recognize that survival